Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: clinical aspects
- PMID: 10376192
- PMCID: PMC6655859
- DOI: 10.1002/clc.4960221404
Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: clinical aspects
Abstract
Invasive and noninvasive arterial imaging are important techniques used to study atherosclerosis and, specifically, to evaluate the atherogenecity of triglyceride-rich lipoproteins (TRL). Serial coronary angiography trials show significant benefit from lowering low-density lipoprotein cholesterol (LDL-C) which serves to retard lesion progression. Even with aggressive LDL-C reduction, however, up to half of patients demonstrate continued progression of atherosclerosis. Angiographic studies reveal that lowering LDL-C has the most impact on severe lesions, those > or = 50% diameter stenosis, whereas TRL (and their apolipoprotein markers) have been identified as a driving factor behind progression of mild-to-moderate lesions < 50% diameter stenosis. Quantitative coronary angiography (QCA) has demonstrated that progression of mild-to-moderate lesions are among the most significant predictors of clinical coronary events, and that lowering TRL reduces progression of coronary artery disease to the same degree as the lowering of LDL-C.
Similar articles
-
Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.Circulation. 1994 Jul;90(1):42-9. doi: 10.1161/01.cir.90.1.42. Circulation. 1994. PMID: 8026027 Clinical Trial.
-
Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: cellular aspects.Clin Cardiol. 1999 Jun;22(6 Suppl):II7-14. doi: 10.1002/clc.4960221403. Clin Cardiol. 1999. PMID: 10376191 Free PMC article. Review.
-
Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size.J Cardiol. 2014 Jan;63(1):60-8. doi: 10.1016/j.jjcc.2013.06.018. Epub 2013 Sep 7. J Cardiol. 2014. PMID: 24016623
-
Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction.Atherosclerosis. 1991 Sep;90(1):67-80. doi: 10.1016/0021-9150(91)90245-x. Atherosclerosis. 1991. PMID: 1799399
-
The role of hypertriglyceridemia in atherosclerosis.Curr Atheroscler Rep. 2007 Aug;9(2):110-5. doi: 10.1007/s11883-007-0006-7. Curr Atheroscler Rep. 2007. PMID: 17877919 Review.
Cited by
-
Fruit and vegetable consumption and hypertriglyceridemia: Korean National Health and Nutrition Examination Surveys (KNHANES) 2007-2009.Eur J Clin Nutr. 2015 Nov;69(11):1193-9. doi: 10.1038/ejcn.2015.77. Epub 2015 May 27. Eur J Clin Nutr. 2015. PMID: 26014266
-
Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.Circ Cardiovasc Genet. 2010 Oct;3(5):462-7. doi: 10.1161/CIRCGENETICS.110.950667. Epub 2010 Aug 21. Circ Cardiovasc Genet. 2010. PMID: 20729559 Free PMC article.
-
Metabolic complications associated with HIV protease inhibitor therapy.Drugs. 2003;63(23):2555-74. doi: 10.2165/00003495-200363230-00001. Drugs. 2003. PMID: 14636077 Review.
-
Role of LXRs in control of lipogenesis.Genes Dev. 2000 Nov 15;14(22):2831-8. doi: 10.1101/gad.850400. Genes Dev. 2000. PMID: 11090131 Free PMC article.
-
Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study.Pharmacogenet Genomics. 2012 May;22(5):367-72. doi: 10.1097/FPC.0b013e328351a486. Pharmacogenet Genomics. 2012. PMID: 22336959 Free PMC article.
References
-
- Blankenhorn DH, Hodis HN: Duff Memorial Lecture: Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994; 14: 177–192 - PubMed
-
- Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH: Triglyceride and cholesterol‐rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994; 90: 42–49 - PubMed
-
- Mack WJ, Krauss RM, Hodis HN: Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS): Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996; 16: 697–704 - PubMed
-
- Alaupovic P, Mack WJ, Knight‐Gibson C, Hodis HN: The role of triglyceride‐rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997; 17: 715–722 - PubMed
-
- Hodis HN, Mack WJ, Dunn M, Liu CR, Liu CH, Selzer RH, Krauss RM: Intermediate‐density lipoproteins and progression of carotid arterial wall intima‐media thickness. Circulation 1997; 95: 2022–2026 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical